Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer

Kornél Lakatos¹, Germán González², Jawad Hoballah³, Jeff Brooker³, Sinyoung Jeong⁴, Conor Evans⁴, Petra Krauledat³, W. Peter Hansen², Kevin M. Elias¹,⁵,⁶, Manish Patankar⁷, Vilmos Fülöp⁸,⁹,¹⁰,¹¹, Panagiotis A. Konstantinopoulos⁶ and Daniel W. Cramer⁵,¹²*

Abstract

Background: Measurement of serum CA125, an antigenic fragment of human mucin 16 (MUC16), is used to monitor the clinical progression of epithelial ovarian cancer (EOC). However, rather than simply a passive marker reflecting tumor burden, MUC16 may have a more active role by binding to immune cells and altering their tumor response. We developed a research tool to measure MUC16-binding to the surfaces of peripheral blood mononuclear cell (PBMC) subtypes and tested its research value using specimens collected serially from a woman being treated for high grade serous EOC.

Methods: Cryopreserved PBMCs were mixed with anti-CA125 antibody-labeled plasmonic gold nanoparticles (PNPs) to detect cell surface MUC16-binding along with fluorescent stains to identify B cells, NK cells, NK-T cells, T cells, and monocytes. From 3D darkfield images, a computer algorithm was applied to enumerate PNP-binding and fluorescence microscopy to identify cell lineage. Average MUC16-binding was determined by fitting a Poisson distribution to PNP-counts across similar cell types. MUC16-binding to cell types was correlated with treatment details, CA125 levels, and complete blood count (CBC) data.

Results: Over a 21-month period, monocytes had the highest level of MUC16-binding which was positively correlated with serum CA125 and inversely correlated with circulating monocyte and lymphocyte counts. Fluctuations of PNP-binding to NK cells were associated temporally with types of chemotherapy and surgical events. Levels of MUC16 bound to NK cells were positively correlated with levels of MUC16 bound to T and NK-T cells and inversely correlated with circulating platelets.

Conclusions: Assessment of MUC16-binding among cryopreserved PBMC cell types can be accomplished using darkfield and fluorescence microscopy. Correlations observed between level of binding by cell type with serum CA125, CBC data, and treatment details suggest that the new techniques may offer novel insights into EOC’s clinical course.

Keywords: Ovarian Cancer, CA125, Mononuclear cells, Nanoparticles, Microscopy

*Correspondence: dcramer@bwh.harvard.edu

¹ Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA, USA

Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
In the search for a reliable biomarker for epithelial ovarian cancer (EOC), mice were immunized with an EOC cell line and splenocytes harvested to look for cancer-specific immune responses. This effort led to the creation of a monoclonal antibody that reacted with sera from most women with EOC [1, 2]. The antibody was called OC125 and the antigen it detected, CA125. CA125 was found to be a larger glycoprotein eventually identified as a member of the mucin family (MUC16) [3]. Higher CA125 levels at presentation of EOC predict poorer survival and serial measurements can be used to predict recurrence [4]. While this could simply reflect greater or increasing tumor burden, observations suggest that MUC16 has a more active role in disease progression by binding to cell surfaces of peripheral blood mononuclear cells (PBMCs) including NK cells and blunting their tumoricidal ability [5–7]. These experiments relied upon fluorescent labels with conventional flow cytometry which may be limited in detecting low levels of cell surface antigens due to auto-fluorescence.

These limitations have been addressed in a series of papers from our group describing technology that opens a new window for assessing the degree of MUC16-binding to PBMCs. This technology involves: 1) plasmonic gold nanoparticles (PNPs) conjugated to anti-CA125 antibodies as optical nanoprobes; 2) high contrast darkfield microscopy to detect PNPs bound to PBMCs and 3) a computational algorithm for automated counting of the bound nanoparticles. PNPs have a unique property called plasmonic resonance, which causes them to strongly scatter specific wavelengths of light to enable single nanoparticle detection. Data were presented from women with EOC showing that their PBMCs (collected before therapy) had greater levels of MUC16 bound to their cell surfaces compared to PBMCs from healthy women [8]. In subsequent work, we improved the technique by adding fluorescence capacities to the microscope, enabling analyses on subsets of PBMCs [9, 10]. EOC cancer patients exhibited higher levels of MUC16 bound to T cells, NK cells and B cells compared to healthy controls [10].

In the study presented here, we now apply the refined technology to longitudinal specimens collected serially from a single patient with advanced serous EOC over a 21-month period of her care. We correlated levels of binding by cell type with serum CA125, CBC data, and treatment details which, we believe, suggest that the new technology can offer novel insights into EOC’s clinical course.

Materials and methods
Clinical specimens
In 2016, we began collecting blood to study MUC16-binding to PBMCs in women with presumed ovarian cancer prior to any therapy and later from healthy women. A patient who had been diagnosed with stage IIIC high-grade serous ovarian knew about the protocol and requested her blood be studied. Diagnosed in 2012, she had undergone suboptimal debulking followed by carboplatin and Taxol chemotherapy. Over the next 8 years, she required additional surgery, additional chemotherapy, and trials of novel therapies. The focus in this paper is the period of her care between 8/2017 and 4/2019. This period is of interest because: the sampling was frequent; there was clinical evidence that the patient’s tumor burden was increasing; and multiple therapies were tried. When clinical specimens were obtained, an extra calcium EDTA blood tube was drawn for the research and processed by the same laboratory to preserve viable PBMCs according to the protocol described [8]. Briefly PBMCs were isolated by Ficoll-density gradient centrifugation, washed in phosphate buffered saline (PBS), re-suspended in complete cell culture medium, and the cell concentration determined. The PBMC were then re-centrifuged and re-dispersed in a mixture of culture media and DMSO. Aliquots of 0.1 ml with cell concentrations of ten million per ml. were created and stored at -80 °C prior to transfer to liquid nitrogen for shipment to PNP facilities in Sterling, VA where the specimens were analyzed.

Preparing specimens and analysis of MUC16 binding to PBMCs.

The process of preparing the specimens for microscopic analysis is similar to that described by González et al. [10]. Briefly, the PBMCs were thawed and stained separately, first with fluorescent antibodies to detect specific subsets of PBMCs and second with gold nanoparticle conjugated with anti-CA125 antibodies to detect cell-surface MUC16. Fluorescent labels for phenotyping T cells, B cells, NK cells and monocytes were obtained from Biolegend (San Diego, CA, USA) and included: BV510 anti-human CD45, BV421 anti-human CD19, AF488 anti-human CD14, PE anti-human CD123, AF647 anti-human CD56(NCAM), and AF647 anti-human CD3 antibody with catalog numbers, 368526, 302234, 325610, 318306, and 300416, respectively. Gold nanoparticles, eighty nanometers in size, conjugated with anti-CA125 antibody were purchased from PNP Research Corporation (Drury, MA, USA, custom conjugation). Gold staining was performed by incubating the sample with gold reagents at a ratio of 10^4 PNPs per cell in 500 uL of PBS with 5% BSA, for five minutes, under continuous mixing conditions. After bound-free nanoparticle separation, samples were reconstituted to a cell density of 25 M cells/ml, in PBS.
with 5% BSA. Microscopy slides were prepared by placing a 9 mm diameter Grace Bio-Labs (Bend, OR, USA) SecureSeal imaging spacer, adding 9.1 µL of the labeled cell solution and sealing it with a coverslip. PBMC specimens, prepared as above, were analyzed by high-contrast darkfield and fluorescent microscopy as described [10]. The imaging platform is oil- and calibration-free and fully automated to acquire large numbers of fields of view and perform simultaneous quantitative PNP detection and qualitative cell lineaging through multiparameter fluorescence microscopy. X–Y stage movement, autofocus- ing modules and automated cell lineaging software allow quantification of PNP binding in low-abundance cell populations. On average, counting of bound PNPs considered 309 cells of the same type per sample (minimum: 17 NK-T cells/sample and maximum 1070 T cells/sample). A Poisson distribution was fit to the PNP-binding events on each cell type. The mean of the Poisson distribution (lambda parameter) corresponds to the average level of MUC16-binding to each immune cell type. We used the exact method to compute a 95% CI for Poisson distributions as described [11]. This method produces non-symmetrical confidence intervals. All computations were made in Python using the Scipy library [12].

Clinical data
Patient information included serum CA125, complete blood count (CBC) with differential, chemotherapy regimens, imaging studies, operative reports, and clinical notes. A CBC could be linked to each of the 30-study bloods collected, and a CA125 value could be associated on the same day for 17 of the samples. The CBC data included: hematocrit, counts of platelets neutrophils, monocytes, eosinophils, basophils, and three constructed ratios (neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR), and lymphocyte-to-monocyte (LMR)). We calculated a Spearman correlation matrix to assess the relationships between average levels of MUC16-binding to each PBMC cell type (B cells, monocytes, NK cells, T cells, and NK-T cells) and serum CA125, and differential counts and ratios. This analysis was performed in SAS v9.4 and all p-values are two-sided.

Results
Figure 1 is a composite image showing examples of the darkfield-intensity projection of bound PNPs and 4-channel fluorescence of cells with different lineage. We applied fluorophore conjugated anti-CD 45 antibodies as a pan-leukocyte marker, visible as green in channel 0. Monocytes were identified with anti-CD14, seen as green on channel 1. B cells were identified using fluorophore conjugated anti-CD19, visible as blue in channel 0. NK cells with anti-CD56, shows as green at channel 0 and orange in channel 1 and channel 2. T cells were identified using anti-CD3, which appear as red in channel 3. Finally, NK-T cells were identified as green in channel 0, orange in channel 1 and 2 and red in channel 3. In this example, monocytes exhibit high CA125 binding, the B cell medium CA125 binding, and other lineages little or no binding.

Figure 2 shows the average numbers of PNPs bound to B cells, NK cells, NK-T cells, T cells, and monocytes over the period, 8/2017 to 4/2019, equating with average levels of MUC16-binding to each cell type. Monocytes had the greatest levels of PNP-binding over the period with counts ranging from about 30 to 65 per cell. Cell types with the smallest levels of binding were NK and T cells with the average PNP-binding ranging between 5–20 per cell.

Fluctuations are seen in MUC16-binding over time with each immune cell type. Potential linkage of these fluctuations with clinical events is illustrated in Fig. 3 for NK cells. Peaks in MUC16-binding to NK cells are seen around 10/2017 and 12/2018—both occurring about 2 months after beginning (or resuming) therapy with bevacizumab. During the time-period, 3/2018 to 9/2018, the patient was receiving oral Olaparib continuously and infusions of the investigational heat shock protein-90 (HSP-90) inhibitor, Olanespib. Except for the cycle beginning early April 2018, sharp declines in the level of MUC16-binding to NK cells were seen on the first day of the infusion cycle, with rebounds occurring about 14 days after the infusion and before the next infusion. Finally, the patient had two surgeries in 2018—a hernia repair and sigmoidectomy for residual disease. Both surgeries were followed by a drop in MUC16-binding to NK cells.

Table 1 highlights significant correlations among the mean levels of MUC16-binding to the immune cell subsets, serum CA125, differential blood counts, and the 3 calculated ratios –PLR, NLR, and LMR. Serum CA125 was positively correlated with averages of MUC16-binding to monocytes (r = 0.58, p = 0.015), with NLR (r = 0.76, p = 0.001), with PLR (r = 0.67, p = 0.003), and inversely correlated with hematocrit (r = -0.54, p = 0.026). Besides their correlation with CA125, mean levels of MUC16-binding to monocytes were inversely correlated with circulating monocytes (r = -0.44, p = 0.015) and lymphocytes (r = -0.57, p = 0.001) and positively correlated with NLR (r = 0.48, p = 0.007) and PLR (r = 0.62, < 0.001). Longitudinal data illustrating the inverse correlations between levels of MUC16-binding to monocytes and circulating monocytes and lymphocytes are illustrated in Fig. 4.

Also in Table 1, levels of MUC16-binding to NK cells were positively correlated with levels of MUC16-binding
to both T cells \( (r = 0.49, p = 0.005) \) and NK-T cells \( (r = 0.43, p = 0.017) \) and inversely correlated with platelet counts \( (r = -0.54, p = 0.002) \). Levels of MUC16-binding to T cells were positively correlated with levels of MUC16-binding to NK-T cells \( (r = 0.39, p = 0.032) \) and inversely correlated with platelet count \( (r = -0.39, p = 0.035) \). Finally, Levels of MUC16 binding to NK-T cells were inversely correlated with eosinophil \( (r = -0.47, p = 0.008) \) and platelet counts \( (r = -0.54, p = 0.002) \). No significant correlations were noted with levels of MUC16-binding to B cells.

**Discussion**

Longitudinally-collected and cryopreserved PBMCs from a patient with high grade serous ovarian cancer during a 21-month period of her clinical care were studied using an instrument that combines fluorescent and darkfield microscopy to quantify the amount of MUC16 binding to T cells, B cells, NK cells, NK-T cells, and monocytes. Patterns of binding were then correlated with clinical data. Our discussion will highlight some of the correlations we think are most important.

Figure 2 illustrates considerable variation over time in levels of MUC16-binding by cell type, which, nevertheless, showed good consistency with respect to how the cells ranked in their level of binding. Thus, levels of MUC16-binding to monocytes were greatest at all time points followed by B cells, NK-T, and NK cells and T cells with the lowest levels. This ranking, in the level of binding by cell type in longitudinal data from a single patient, matches the order in the degree of binding in

---

**Fig. 1** Composite image showing darkfield maximum intensity projection and 4 channel fluorescence of different cell lineages. Legend: Monocytes exhibit high PNP-binding, the B cell medium PNP-binding, and other lineages little or no binding. Fluorophore conjugated anti-CD 45 antibodies were applied as a pan-leukocyte marker visible as green in channel 0. Monocytes were identified with fluorophore conjugated anti-CD14 seen as green on channel 1. B cells were identified using fluorophore conjugated anti-CD 19, visible as blue in channel 0. NK cells with fluorophore conjugated anti-CD56, shows as green at channel 0 and orange in channel 1 and channel 2. T cells were identified using fluorophore conjugated anti-CD3, which appear as red in channel 3. Finally, NK-T cells were identified as green in channel 0, orange in channel 1 and 2 and red in channel 3.
the individual cases reported previously [10]. The ranking may be explained by the degree of expression on white cell surfaces of MUC16’s principal binding partner, Siglec-9 (sialic acid binding Ig-like lectin). Siglec-9 expression among leukocytes has been found to be highest on monocytes, intermediate on neutrophils, and weaker on lymphocytes, including NK and T cells [13]. Thus, degree of Siglec-9 expression on leukocytes appears to explain differences in the degree of MUC-16 binding. MUC16-binding to neutrophils also occurs but was not studied here since these are removed during cryopreservation of PBMCs. Although the relative order of binding by cell type was the same between the current and prior study, the case in the current study had levels of binding that were higher for each of the cell types than those seen for the cases in our prior report [10]. This is likely due to the higher ratio of PNPs to cells used to perform gold staining in the set of specimens used in the current study.

We selected NK cells to correlate with details of the patient’s clinical course because of the previous work describing MUC16 inhibition of synapse formation between NK cells and ovarian cancer tumor cells, thus preventing NK-cell tumoricidal function [5–7]. One of the more interesting aspects of Fig. 3 were the troughs and rebounds in MUC16-binding to the NK cells that were seen during February and August 2018, and appeared, in most instances, to coincide with the infusions of the HSP-90 inhibitor, olanespib. Anti-HSP90 treatment is known to modify expression of activating receptors on NK cells [14], although no specific effect of HSP-90 inhibitors on Siglec-9 receptors has been described. Also, of potential interest, peaks in MUC16 binding to NK cells were seen around 10/2017 and 12/2018—both occurred about 2 months after beginning (or resuming) therapy with bevacizumab. An elevation of NK cells has been described in a clinical trial involving bevacizumab and renal cell carcinoma [15]. Finally, a drop in MUC16-binding to NK cells was seen after the patient’s two surgeries. Abdominal surgery appears to lower NK cell count both experimentally [16] and after primary surgery for ovarian cancer [17]. However, we should note that, in all three of these reports, the increase [15] or decreases [16, 17] relate to NK cell counts and not directly to MUC16-binding to NK cells which was the focus of this report.
Although the clinical correlations noted above must be viewed as descriptive, significance can be attached to the correlations pointed out in Table 1. The only correlation between serum CA125 and binding of MUC16 to the PBMC subtypes was a positive one with MUC16-binding to monocytes ($r = 0.58$, $p = 0.01$). This likely reflects the higher level of Siglec-9 expression on monocytes [13]. The fact that no correlation was seen between serum CA125 and monocyte binding among individual cases in the prior study [10] suggests that there are greater interpersonal than intrapersonal factors that affect the correlation between surface bound MUC16 and serum CA125. In our study, serum CA125 also correlated with the leukocyte ratios, NLR and PLR. Both of the latter correlations have been previously described in women with ovarian cancer using cross-sectional data [18], but we believe this is the first report that the correlations also exist in longitudinal specimens from the same patient. Indeed, the correlation between serum CA125 and NLR of $r = 0.76$, $p = 0.001$ was surprisingly strong based on only 17 observations. CA125 was also weakly and inversely correlated with the patient’s hematocrit likely suggesting chemotherapy-associated anemia, especially with Olaparib, which the patient was on for much of this period [19]. In addition, anemia occurs as a consequence of low erythropoietin response in patients with solid tumors that is, to some extent, independent of chemotherapy [20].

The inverse correlations between monocyte binding and circulating monocyte and lymphocyte counts illustrated in Fig. 3 are also of interest. After entering the blood stream from the bone marrow, monocytes usually infiltrate a wide variety of tissues and become dendritic cells or macrophages [21]. Some also return to the lymph nodes carrying antigens they were previously exposed to, keeping their monocyte form [22]. In either case, these events could lead to a decline in circulating monocytes if MUC16-binding to monocytes promoted macrophage differentiation and/or migration to lymph nodes or other sites of cancer metastases. Increasing

Fig. 3 Average PNP-binding to NK cells at time points of clinical events during 8/2017 to 4/2019. Legend: A rise in NK cell PNP-binding started after beginning Bevacizumab in 10/2017 and resuming it in 12/2018. The patient had two abdominal surgeries indicated by the green and red arrows. The start and end points of the Onalespib/Olaparib cycles are indicated in the yellow background section with each cycle beginning with I.V. administrations of Onalespib.
### Table 1  Significant correlations among levels of MUC-16 binding to PBMC cell types, CA125, and blood count

| Statistic | B-cell mean | Mono-ocyte mean | NK-cell mean | T-cell mean | NK-T cell mean | Neutrophils | Monocytes | Lymphocytes | Eosinophils | Basophils | NLR | PLR | LMR | Hematocrit | Platelet |
|-----------|-------------|-----------------|--------------|-------------|----------------|-------------|-----------|-------------|-------------|-----------|-----|-----|-----|-----------|----------|
| CA125     | r           | NS              | 0.58         | NS          | NS             | NS          | NS        | NS          | NS          | NS        | 0.76| 0.67| NS  | -0.54     | NS       |
| p         | 0.015       | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | 0.001| 0.003| 0.026| NS        | NS       |
| p-value   | 0.015       | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | 0.001| 0.003| 0.026| NS        | NS       |
| n         | 17          | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | 17   | 17   | 17   | NS        | NS       |
| B-cell mean | r           | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | NS  | NS  | NS  | NS        | NS       |
| p         | 0.015       | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | NS  | NS  | NS  | NS        | NS       |
| p-value   | 0.015       | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | NS  | NS  | NS  | NS        | NS       |
| n         | 30          | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | 30   | 30   | 30   | NS        | NS       |
| Monocyte mean | r           | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | NS  | NS  | NS  | NS        | NS       |
| p         | 0.49        | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | NS  | NS  | NS  | NS        | NS       |
| p-value   | 0.005       | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | NS  | NS  | NS  | NS        | NS       |
| n         | 30          | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | 30   | 30   | 30   | NS        | NS       |
| NK-cell mean | r           | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | NS  | NS  | NS  | NS        | NS       |
| p         | 0.017       | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | NS  | NS  | NS  | NS        | NS       |
| p-value   | 0.017       | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | NS  | NS  | NS  | NS        | NS       |
| n         | 30          | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | 30   | 30   | 30   | NS        | NS       |
| T-cell mean | r           | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | NS  | NS  | NS  | NS        | NS       |
| p         | 0.032       | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | NS  | NS  | NS  | NS        | NS       |
| p-value   | 0.032       | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | NS  | NS  | NS  | NS        | NS       |
| n         | 30          | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | 30   | 30   | 30   | NS        | NS       |
| NK-T cell mean | r           | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | NS  | NS  | NS  | NS        | NS       |
| p         | 0.008       | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | NS  | NS  | NS  | NS        | NS       |
| p-value   | 0.008       | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | NS  | NS  | NS  | NS        | NS       |
| n         | 30          | NS              | NS          | NS          | NS             | NS          | NS        | NS          | NS          | NS        | 30   | 30   | 30   | NS        | NS       |

**Abbreviations:** NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, LMR lymphocyte-to-monocyte ratio, r Spearman correlation coefficient, p p-value, n number of data points, NS not significant.
expression of the Siglec-9 (or Siglec-7) receptor on mononuclear cells with cancer likely underlies either their differentiation or migration to the tumor or metastatic sites. It has been demonstrated that pancreatic tumors, through the expression of sialic acids on their cell surface engage Siglec-7 and Siglec-9 to mediate monocyte to macrophage differentiation [23]. Additionally, another study demonstrated that Siglec-9 expression is upregulated on tumor infiltrating T cells in lung, colorectal and ovarian cancers [24]. An explanation for the inverse correlation of MUC16-binding to monocytes with circulating lymphocytes is less clear; but macrophage plasticity and interaction with lymphocytes subsets may be relevant [25].

Similar to findings among individual cases in the prior study [10], we saw positive correlations between levels of MUC16-binding to NK cells and T cells as well as levels of MUC16-binding to NK-T cells and T cells. This may reflect overlapping of markers for distinguishing these subsets. In our study, levels of MUC16-binding to all three of these subsets was inversely correlated with the platelet count. This is of interest because activated platelets enhance T cell, cytotoxic T cell, NK cell, and B cell infiltration of tissue and subsequent migration to sites of tissue inflammation, such as occurs with solid tumors. Better understanding of platelet-lymphocyte “cross-talk” as described by Li [26] and how this affects MUC16-binding awaits the development of routine methods for specifically identifying and counting activated platelets.

In conclusion, we have described the application of a novel imaging platform that combines darkfield and fluorescent microscopic techniques to quantify binding of MUC16 to longitudinally collected PBMC subtypes in a patient with EOC. MUC16-binding to monocytes and to NK cells appeared to correlate best with CA125 and CBC data as well as clinical events—if only on a descriptive basis for the latter. Besides illustrating the potential values of the imaging platform in clinical research, we believe this work also establishes the potential research value of longitudinally collected and cryopreserved PBMCs which, we believe, are currently underutilized in cancer research.

Acknowledgements
We are grateful for the selfless participation of Patient LR during her courageous battle with ovarian cancer to whom this work is dedicated.
Authors’ contributions
1. Clinical input VF, RE, GG, PAK, 2. Conceptualization DC, MP, GG, SJ, CE, PK, PH, 3. Data Handling / Analysis DC, CE, PK, PH, 4. Funding/Resources GG, JB, SJ, PK, PH, 5. Instrument development/methodology JB, SJ, CE, 6. Laboratory work KE, KL, GG, JH, 7. Manuscript—original draft DC, MP, KL, PK, PH, PAK, 8. Manuscript—Review and editing—all Authors, 9. Project administration DC, PK, PH, 10. Supervision KE, VF, MP, JH, CE, 11. Validation: MP. The author(s) read and approved the final manuscript.

Funding
Supported by a grant from the National Cancer Institute Grant number SR33CA197605.

Availability of data and materials
The data that support the findings of this study are available upon request to the corresponding author with appropriate institutional approvals. The data are not publicly available due to privacy and ethical restrictions.

Declarations

Ethics approval and consent to participate
In 2016, we began collecting blood to study MUC16-binding to PBMCs in women with presumed ovarian cancer prior to any therapy at the Dana Farber Cancer Institute (DFCI IRB protocol 16–255) and later from healthy women through the Brigham and Women’s Hospital (BWH IRB protocol 2018P00677). A patient who had been diagnosed with stage IIC high-grade serous ovarian cancer learned about the protocol and requested her blood be studied. She was informed that results could not be used in her clinical care, provided consent, and granted a single-subject IRB exemption. IRB approval from Brigham and Women’s Hospital Institutional Review Board and patient consent were obtained for this study; a copy of the consent form is on file.

Consent for publication
All authors agreed to the publication of this data.

Competing interests
G.G., W.P.H. and P.K. are employees of Thorlabs Imaging Sciences.

Author details
1 Gynecologic Oncology Laboratory, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. 2Thorlabs Imaging Systems, 108 Powers Ct, Sterling, VA 20166, USA. 3Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 20114, USA. 4Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA, USA. 5Dana-Farber Cancer Institute, 75 Francis Street, Boston, MA 20115, USA. 6Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, WI, USA. 7Department of Obstetrics and Gynecology, Military Hospital Medical Centre, Hungarian Defense Forces, Budapest, Hungary. 8Faculty of Healthcare, University of Miskolc, Miskolc, Hungary. 9Semmelweis University, Budapest, Hungary. 10Clinical Medicine Doctoral School, University of Szeged, Szeged, Hungary. 11Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital, 221 Longwood Avenue, Boston, MA 02115, USA.

Received: 22 July 2021   Accepted: 3 February 2022

Published online: 26 February 2022

References
1. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68(5):1353–7.
2. Bast RC Jr, Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309(15):883–7.
3. Lloyd KO, Yin BW, Kudryashov V. Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule. Int J Cancer. 1997;71(5):842–50.
4. Gupta D, Liu G. Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. J Ovarian Res. 2009;2:13.
5. Belisle JA, Gubbelks JA, Raphael CA, Migneault M, Rancourt C, Connor JP, et al. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology. 2007;122(3):418–29.
6. Belisle JA, Horibata S, Jennifer GA, Petrie S, Kapur A, Andre S, et al. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer. 2010;9:118.
7. Gubbelks JA, Felder M, Horibata S, Belisle JA, Kapur A, Holden H, et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer. 2010;9:11.
8. Jeong S, Gonzalez G, Ho A, Nowell H, Austin LA, Hoballah J, et al. Plasmonic Nanoparticle-Based Digital Cytometry to Quantify MUC16 Binding on the Surface of Leukocytes in Ovarian Cancer. ACS Sens. 2020;5(9):2772–82.
9. Peng F, Jeong S, Gonzalez G, Marks H, Ho A, Roussakis E, et al. Assessment of Glial Fibrillary Acidic Protein Binding to the Surface of Leukocytes with Dark-Field Imaging and Computational Analysis. Adv Funct Materials. 2021;31(11):2009229.
10. Gonzalez G, Lakatos K, Hoballah J, Fritz-Klaus R, Al-Johani L, Broker J, et al. Characterization of Cell-Bound CA125 on Immune Cell Subtypes of Ovarian Cancer Patients Using a Novel Imaging Platform. Cancers (Basel). 2021;13(9):2072.
11. Ulim K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol. 1990;131(2):373–5.
12. Virtanen P, Gormers R, Cliphant TE, Haberland M, Reddy T, Courneyea D, et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nature Methods. 2020;17(3):261–72.
13. Zhang JQ, Nicol G, Jones C, Crocker PR. Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes. J Biol Chem. 2000;275(29):22121–6.
14. Bae J, Munishi A, Li C, Samur M, Prabhala R, Mitsiades C, et al. Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol. 2013;190(3):1360–71.
15. Wang Q, Qin J, Liu X. Analysis of efficacy of sorafenib combined with vascular endothelial growth factor inhibitor Avastin in renal cell carcinoma. J Biomed. 2019;24(4):1638–625.
16. Toft P, Dagnæs-Hansen F, Tønnesen E, Petersen MS. Influence of surgery and endotoxin-induced sepsis combined on natural killer cell activity, oxidative burst of granulocytes and antigen presentation capability of monocytes. Acta Anaesthesiol Scand. 2002;46(4):405–9.
17. Lukomska B, Olzewski WL, Engeset A, Kolstad P. The effect of surgery and chemotherapy on blood NK cell activity in patients with ovarian cancer. Cancer. 1983;51(3):465–9.
18. Cramer DW, Benjamin WJ IV, Vitorsen AF, Berkowitz R, Goodman A, Matulonis U. Differential blood count as triage tool in evaluation of pelvic masses. Int J Gynecol Cancer. 2020;31(3):733–43. https://doi.org/10.1136/ijgc-2019-001103.
19. Ruiz-Schutz VC, Gomes LM, Mariano RC, de Almeida DVP, Pimenta JM, Dal Molin GZ, et al. Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials. Curr Rev Oncol Hematol. 2019;14:161–73.
20. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990;322(24):1689–92.
21. Jakubzick C, Gautier EL, Gibbings SL, Sojka DK, Schlitzer A, Johnson J, et al. Characterization of Siglec receptors Siglec-7 and Siglec-9 as mucin-type molecules. Immunology. 2007;122(3):418–29.
24. Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S, et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Invest. 2018;128(11):4912–23.
25. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–96.
26. Kim SY, Kim JE, Kim HK, Han KS, Toh CH. Accuracy of platelet counting by automated hematologic analyzers in acute leukemia and disseminated intravascular coagulation: potential effects of platelet activation. Am J Clin Pathol. 2010;134(4):634–47.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.